<div id="readability-page-1"><p>Alps Advisors Inc. trimmed its holdings in  AbbVie Inc. (NYSE:ABBV - Free Report) by 26.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 121,867 shares of the company's stock after selling 44,294 shares during the period. Alps Advisors Inc.'s holdings in AbbVie were worth $28,217,000 as of its most recent filing with the Securities and Exchange Commission.</p><ul><li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li></ul><p>A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ABBV. Norges Bank purchased a new stake in  AbbVie during the 2nd quarter worth about $4,288,200,000.  Laurel Wealth Advisors LLC boosted its stake in shares of  AbbVie by 18,384.4% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company's stock worth $1,059,141,000 after purchasing an additional 5,675,095 shares during the last quarter.  Vanguard Group Inc. boosted its position in  AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares during the last quarter.  DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of  AbbVie by 169.3% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company's stock worth $876,662,000 after purchasing an additional 2,969,202 shares during the last quarter.  Finally, Raymond James Financial Inc. boosted its stake in  AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. Institutional investors and hedge funds own  70.23% of the company's stock. </p><h2>AbbVie Stock Performance</h2><p>ABBV stock opened at $223.50 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market capitalization of $395.01 billion, a price-to-earnings ratio of 94.70, a PEG ratio of 0.91 and a beta of 0.35. The stock's fifty day moving average is $223.74 and its two-hundred day moving average is $219.63. </p><ul><li>3 “Forever Stocks” to Hold When the Market Won’t Sit Still</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. AbbVie's revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS.  As a group, analysts predict that  AbbVie Inc. will post 12.31 EPS for the current fiscal year. </p><h2>AbbVie News Summary</h2><p>Here are the key news stories impacting AbbVie this week:</p><ul>   <li><span>Positive Sentiment: </span>Morgan Stanley raised its price target to $270 and kept an &#34;overweight&#34; call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.</li>    <li><span>Positive Sentiment: </span>Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.</li>    <li><span>Positive Sentiment: </span>Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.</li>    <li><span>Positive Sentiment: </span>New real‑world Rinvoq data from Japan bolsters the drug's addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.</li>    <li><span>Neutral Sentiment: </span>Management framed the earnings call around &#34;new growth engines&#34; — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn't eliminate near‑term volatility. Read More.</li>    <li><span>Neutral Sentiment: </span>Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.</li>    <li><span>Negative Sentiment: </span>Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.</li>    <li><span>Negative Sentiment: </span>AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.</li>    <li><span>Negative Sentiment: </span>Broader coverage highlighted investor &#34;angst&#34; and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.</li> </ul><h2>Analyst Upgrades and Downgrades</h2><ul><li>AbbVie Call Options Spike 2,599%: Tracking the Big Bet</li></ul><p>ABBV has been the topic of several research analyst reports. Wall Street Zen lowered AbbVie from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, January 3rd. JPMorgan Chase &amp; Co. raised their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 3rd. Sanford C. Bernstein  reissued a &#34;market perform&#34; rating on shares of AbbVie in a report on Thursday. Scotiabank began coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $280.00 target price on the stock. Finally, UBS Group decreased their price target on AbbVie from $240.00 to $230.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued  a Buy rating and nine have assigned  a Hold rating to the company's stock. According to data from MarketBeat.com, AbbVie currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $251.00.</p><p><b>View Our Latest Stock Analysis on AbbVie</b></p><h2>AbbVie Profile</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than AbbVie</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The $650 Million Bet on AI's Future</li><li>The gold chart Wall Street is terrified of…</li><li>The buying spree that no one is talking about</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Alps Advisors Inc. reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 26.7% in Q3, now owning 121,867 shares valued at $28.2 million. Other institutional investors, including Norges Bank and Vanguard Group, have also adjusted their stakes in AbbVie. The stock opened at $223.50, with a market cap of $395.01 billion. AbbVie reported Q4 earnings of $2.71 EPS, exceeding estimates, and projected FY 2026 EPS guidance between 14.370-14.570. Analysts remain optimistic about AbbVie’s growth prospects, particularly in immunology drugs, despite some near-term volatility.</p>

Market Beat

Invesco Biotechnology & Genome ETF

Abbvie

SPDR S&P Biotech

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VG Health

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares US Pharma

AbbVie Inc. $ABBV Shares Sold by Alps Advisors Inc.